Monday, February 5, 2018

Cotinga Pharmaceuticals Inc. - COT.v

Cotinga Pharmaceuticals Inc. - COT.v represents a multi-pronged approach to value creation in the biopharmaceutical space.

In addition to a potential breakthrough treatment for many cancers, COTI has a robust pipeline of compounds, R&D collaborations and other applications of its core technology.

On January 25, 2018 the company released News

Cotinga Pharmaceuticals Inc. (formerly Critical Outcome Technologies Inc.) (TSX Venture: COT; OTCQB: COTQF) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced the publication of positive data from a preclinical study demonstrating that combining COTI-2 with commonly used chemotherapeutic agents improves efficacy and exhibits a favorable drug resistance and toxicity profile in human cancer cell lines.